Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Melanoma
Research from University of Michigan in the area of melanoma published
September 24th, 2008
According to recent research published in the Journal of Immunotherapy, "Twenty-four subjects with metastatic melanoma were treated on a randomized Phase Ib trial evaluating an autologous tumor lysate-pulsed dendritic cell (DC) vaccine with or without interleukin (IL)-2. The vaccine consisted of autologous DCs obtained from peripheral blood mononuclear cells (PBMCs) cultured in granulocyte macrophage-colony stimulating factor and IL-4 then pulsed with autologous tumor cell lysate and keyhole limpet hemocyanin (KLH)." "The primary end points of the trial were safety and immune response to vaccine. Subjects were randomized to vaccine administered every other week...
Source: Vaccine Weekly (2008-09-24)
|
